PDF
ePub
Citation
Print
Abstract
Osteoarthritis (OA) is a common, chronic, and painful disorder characterized by cartilage loss. It is the most common among all rheumatic disorders and is a major cause of disability. OA can be managed with a variety of pharmacological therapies, including acetaminophen, traditional nonsteroidal anti-inflammatory drugs, cyclooxygenase-2 inhibitors, intra-articular steroids, viscosupplements, glucosamine, chondroitin sulfate, and capsaicin. In this review, I describe the clinical efficacy and side effects of these pharmaceuticals and review disease-modifying osteoarthritis drugs (DMOAD), such as glucosamine, diacerein, and avocado/soybean unsaponifiables, of which the clinical efficacy still remains to be determined.
References
1. American College of Rheumatology subcommittee on osteoarthritis guidelines. [Special Articles] Recommendation for the medical management of osteoarthritis of the hip and knee : 2000 update. Arthirtis Rheum. 2000. 43:1905–1915.
2. NIH Conference. Osteoarthritis : New Insights, part I : The disease and its risk factors. Ann Intern Med. 2000. 133:635–646.
3. Sowers MF. Epidemiology of risk factors for osteoarthritis : systemic factors. Curr Opin Rheummatol. 2001. 13:447–451.
4. Sharma L. Local factors in osteoarthritis. Curr Opin Rheummatol. 2001. 13:441–446.
5. Doherty M. Risk factors for progression of knee osteoarthritis. Lancet. 2001. 358:775–776.
6. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum. 1998. 41(8):1343–1355.
7. Jacobsson , Lennart TH. The epidemiology of osteoarthritis in the peripheral joints : definitions of osteoarthritis in the knee and hand. Ann Rheum Dis. 1996. 55(9):656–658.
8. Schouten Jan SAG, de Bie RA, Swaen G. An update on the relationship between occupational factors and osteoarthritis of the hip and knee. Curr Opin Rheummatol. 2002. 14:89–92.
9. Pelletier JP, Johanne MP, Abramson SB. Osteoarthritis, an inflammatory disease. Potential complication for the selection of new therapeutic targets. Arthritis Rheum. 2001. 41(6):1237–1247.
10. Altman RD, Hochberg MC, Moskowitz RW, Schnitzer TJ. Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum. 2000. 43(9):1905–1915.
11. Felson DT, Lawrence RC, Hochberg MC, McAlindon T, Dieppe PA, Minor MA, et al. NIH conference, New insights, Part 2 : Treatment approaches. Ann Intern Med. 2000. 133:726–737.
12. Pendleton A, Arden N, Dougados M, Doherty M, Bannwarth B, Bijlsma JWJ, et al. EULAR recommendations for the management of knee osteoarthritis : report of a task force of the standing committee for international clinical studies including therapeutic trials (ESCISIT). Ann Rheum Dis. 2000. 59:936–944.
13. Jubb RW. Oral and intra-articular remedies : Review of papers published from March 2001 to February 2002. Curr Opin Rheummatol. 2002. 14:597–602.
14. Hawkey CJ. COX-2 inhibitors. Lancet. 1999. 353:307–314.
15. Maxime D, Minh N, Laurent B, Bernard M, Eric V, Michel L. Evaluation of the structure-modifying effects of diacerein in hip osteoarthiritis : ECHODIAH, a three-year, placebo-controlled trial. Arthirtis Rheum. 2001. 44:2539–2547.
16. Forent R, Oliver B, Olivier E, Michel C, Yves H, Jean-Yves R. Structural and symptomatic efficacy of glucosamine and chodroitin in knee osteoarthritis : A comprehensive meta-analysis. Arch Intern Med. 2003. 163:1514–1522.
17. Michel L, Emmanuel M, Christian C, Renée-Liliane D. Structural effect of avocado/soybean unsaponifiables on joint space loss in osteoarthritis of the hip. Arthritis Care Res. 2003. 47(1):50–58.
XML Download